SAN DIEGO, April 28, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced that the Obalon Balloon System was featured this afternoon in the “Premier Global Hot Topics” panel at the Aesthetic Meeting 2017, the annual meeting for The American Society of Plastic Surgery (ASAPS) and The Aesthetic Surgery Education and Research Foundation (ASERF). The presentation, "New, Gastric Balloon Technologies for Weight Loss," was presented by Grant Stevens, MD, a plastic surgeon with a practice in Marina Del Ray, CA.
"Hot Topics, one of the most popular sessions of the annual meeting, is about new and emerging technologies. It seemed only fitting that I present the Obalon Balloon System technology during that session," said Dr. Stevens. "This innovative device could be the wave of the future for assisting obese patients with weight loss and allows doctors to expand their practice with a new product offering that can potentially change people’s lives.”
The Obalon Balloon System was approved by the Food and Drug Administration (FDA) in September 2016. It is a swallowable intragastric balloon system indicated for temporary use to facilitate weight loss in adults with obesity (BMI of 30 – 40 kg/m2) who have failed to lose weight through diet and exercise. Three (3) Obalon Balloons are placed in the stomach within the first three months of the six-month treatment period. All balloons must be removed six months after the first balloon is placed.
In addition to the Hot Topics panel, Dr. Stevens will also present data about the Obalon Balloon System at a Practice Changers presentation on April 29th titled “A Novel, FDA Approved Approach to Weight Loss, Patient Acquisition and Body Contouring.”
“I decided to bring the Obalon Balloon System into my practice because often diet and exercise are not enough and this device offers an additional way for people to achieve the results they are looking for,” said Dr. Stevens. “The Obalon Balloon System targets obesity using a new method and I am thrilled to be sharing my experience with my fellow plastic surgeons attending the Aesthetic Meeting.”
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the benefits of the company’s product and the anticipated presentation of data about the company’s product. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to achieve or sustain profitability; the company’s ability to predict its future prospects and forecast its financial performance and growth; the rate at which physicians and patients adopt and use the company’s balloon system; the effect of adverse events or other negative developments involving other companies’ intragastric balloons or other obesity treatments; the company’s ability to educate physicians on safe and proper use of the Obalon balloon system; the rate at which patients may experience serious adverse device events as the result of the misuse or malfunction of, or design flaws in, the company’s products; the company’s ability to obtain FDA approval or other regulatory approvals for its future products and product improvements; the company’s ability to adequately protect its proprietary technology and maintain its issued patents and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.